adc
No description yet: the sentence for this tag has not been written. 12 records carry it: 12 people.
Related tags
12 records
| Cancers | Other tags | ||||
|---|---|---|---|---|---|
Aditya Bardia Professor of Medicine and Director of Translational Research Integration, UCLA Jonsson Comprehensive Cancer Center · UCLA Jonsson Comprehensive Cancer Center Led ASCENT, the trial that made sacituzumab govitecan the first ADC for triple-negative breast cancer, and the EMERALD trial of elacestrant. | Triple-negative breast cancer, HR-positive / HER2-negative breast cancer | none | breast, trialist | ||
Cristina Saura Head of the Breast Cancer Unit, Vall d'Hebron University Hospital and VHIO · Vall d'Hebron University Hospital / VHIO Spanish breast oncologist leading DESTINY-Breast09, which moved trastuzumab deruxtecan into first-line HER2-positive disease. | HER2-positive breast cancer | none | breast, her2 | ||
Hervé Tilly Professor of Hematology, Centre Henri Becquerel and University of Rouen; LYSA · LYSA (The Lymphoma Study Association) Principal investigator of POLARIX, the trial that gave DLBCL its first improvement on R-CHOP in twenty years. | Diffuse large B-cell lymphoma | none | lymphoma, lysa | ||
Ian E. Krop Associate Cancer Center Director for Clinical Research, Yale Cancer Center · Yale Cancer Center / Smilow Cancer Hospital Breast oncologist who took T-DM1 and then trastuzumab deruxtecan from first-in-human studies to approval. | HER2-positive breast cancer | none | breast, her2 | ||
Ignace Vergote Emeritus Professor of Gynaecologic Oncology, University Hospitals Leuven; Chair, BGOG and ENGOT · UZ Leuven / Leuven Cancer Institute Led the EORTC trial that made neoadjuvant chemotherapy acceptable in ovarian cancer and innovaTV 301, the first ADC survival win in cervical cancer. | Ovarian cancer, Cervical cancer | none | ovarian, cervical, cooperative-group | ||
Jonathan E. Rosenberg Chief, Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center · Memorial Sloan Kettering Cancer Center Led the early enfortumab vedotin trials and the atezolizumab study that first brought immunotherapy to bladder cancer. | Bladder & urothelial cancer | none | urothelial, immunotherapy | ||
Joseph M. Connors Clinical Professor Emeritus, BC Cancer Centre for Lymphoid Cancer, University of British Columbia · BC Cancer Led ECHELON-1, which replaced bleomycin with brentuximab vedotin in first-line advanced Hodgkin lymphoma. | Hodgkin lymphoma | none | hodgkin, canada | ||
Kathleen N. Moore Associate Director of Clinical Research, Stephenson Cancer Center, University of Oklahoma · Stephenson Cancer Center, OU Health Led SOLO-1 and MIRASOL, which gave ovarian cancer a maintenance PARP inhibitor and its first ADC with a survival benefit. | Ovarian cancer | none | ovarian, parp, trialist | ||
Sagar Lonial Chair of Hematology and Medical Oncology and Chief Medical Officer, Winship Cancer Institute of Emory University · Winship Cancer Institute of Emory University Led SIRIUS and the DREAMM programme, bringing daratumumab monotherapy and the BCMA ADC belantamab to myeloma. | Multiple myeloma | none | myeloma, swog | ||
Shanu Modi Breast Medical Oncologist, Memorial Sloan Kettering Cancer Center · Memorial Sloan Kettering Cancer Center Led DESTINY-Breast01 and DESTINY-Breast04, the trials that created the HER2-low category and opened T-DXd to most breast cancers. | HER2-positive breast cancer, HR-positive / HER2-negative breast cancer, Triple-negative breast cancer | none | breast, her2-low | ||
Steven M. Horwitz Attending Physician, Lymphoma Service, Memorial Sloan Kettering Cancer Center · Memorial Sloan Kettering Cancer Center Led ECHELON-2, the first trial to improve survival in peripheral T-cell lymphoma, using brentuximab vedotin. | Peripheral T-cell lymphomas | none | lymphoma, t-cell | ||
Thomas Powles Professor of Genitourinary Oncology and Director, Barts Cancer Centre, Queen Mary University of London · Barts Cancer Institute / Barts Health NHS Trust Led EV-302, NIAGARA and IMvigor011, the trials that transformed bladder cancer from chemotherapy-only to ADC, immunotherapy and ctDNA-guided care. | Bladder & urothelial cancer, Renal cell carcinoma | none | urothelial, ctdna, trialist |
